LIFE, US0021202025

aTyr Pharma stock advances after FDA aligns on Phase 3 study

Published on 10/06/2026 at 12:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

aTyr Pharma stock was last at USD 0.29 on Nasdaq on October 5, 2026, while nine analysts put the median target at USD 3.00. The Phase 3 study may enroll 372 patients.

LIFE, US0021202025, Illustration mit AI erstellt.

aTyr Pharma (ISIN US0021202025) was last at USD 0.29 on Nasdaq on October 5, 2026, up 0.97 percent from the prior close. The company has aligned with the FDA on a global Phase 3 study of efzofitimod, giving its lead program a defined regulatory path.

FDA alignment sets the trial design

According to GlobeNewswire on September 24, 2026, aTyr will study efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The 54-week trial is designed to enroll up to 372 patients, with forced vital capacity at week 48 as the primary endpoint and the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint.

The study would compare 5.0 mg/kg efzofitimod with placebo, using intravenous dosing once every three weeks for 17 doses. aTyr expects to begin study-related activities in the fourth quarter of 2026, but the company said future development will require additional capital.

Losses narrow as spending is reset

StockTitan reported on August 7, 2026, that aTyr's second-quarter net loss narrowed to USD 10.3 million, or USD 0.11 per share, from USD 19.5 million, or USD 0.22 per share, in the year-earlier quarter. Operating expenses were USD 10.9 million, including USD 6.7 million for research and development and USD 4.1 million for general and administrative costs.

The restructuring included a workforce reduction of 60 percent and cost measures expected to reduce annualized operating expenses by USD 13 million beginning in the fourth quarter of 2026. Cash, cash equivalents, restricted cash and investments stood at USD 58.9 million on June 30, 2026, making financing capacity a central issue as the Phase 3 program moves forward.

Analysts see a wide valuation gap

According to Ticker Nerd on October 3, 2026, nine analysts publish a median 12-month price target of USD 3.00, with targets ranging from USD 1.00 to USD 7.00. Against the October 5 price of USD 0.29, the median target is a wide numerical gap, but it depends on successful development and additional funding.

Stock remains below one dollar

aTyr Pharma stock was last at USD 0.29 on Nasdaq on October 5, 2026, with a 52-week range of USD 0.27 to USD 1.12, volume of 1,786,089 shares and a market capitalization of USD 28.4 million. The next key valuation test is whether the FDA-aligned trial plan can translate into funded clinical execution.